Date: 2015-08-04
Type of information: Nomination
Compound:
Company: Allena Pharmaceuticals (USA - MA)
Therapeutic area: Rare diseases - Metabolic diseases
Type agreement:
Action mechanism:
Disease:
Details: * On August 4, 2015, Allena Pharmaceuticals, a specialty biopharmaceutical company focused on developing and commercializing innovative, non-systemic, oral protein therapeutics to treat metabolic and orphan diseases, announced that the company has expanded its leadership team with the appointment of Annamaria Kausz, M.D., as vice president of clinical development. As Allena’s vice president of clinical development, Dr. Kausz, an adult and pediatric nephrologist, brings to Allena nearly a decade of industry experience in pharmaceutical clinical development and regulatory strategy. Dr. Kausz joins Allena from EMD-Serono, where she led the development of early-stage immunology compounds. She has played key roles in the clinical programs and the regulatory applications for chronic kidney disease therapies Auryxia™ at Keryx Biopharmaceuticals and Feraheme® at AMAG Pharmaceuticals. Dr. Kausz earned an M.D. from the University of Virginia and an M.S. in epidemiology from the University of Washington. She completed her residency in internal medicine and pediatrics at the University of North Carolina, and her fellowships in nephrology and pediatric nephrology at the University of Washington Hospital and Seattle Children’s Hospital.
Financial terms:
Latest news:
